跳至主要内容
临床试验/NCT00462618
NCT00462618已完成2 期

Group Cognitive Behavioral Therapy (CBT I) Vs. Quetiapine for Residual Insomnia Impairing Recovery Among Elderly With Stable Major Affective Disorders

Michael E. DeBakey VA Medical Center1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2007年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
32
试验地点
1
主要终点
PTSQ

研究概览

简要总结

The purpose of this pilot study is to assess feasibility and patient accessibility in order to design an adequately powered study to compare group cognitive behavioral therapy for insomnia (CBT-I) to quetiapine in non-demented patients aged 60 years or older with controlled bipolar disorder (I or II) or major depressive disorder who suffer from residual insomnia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age greater or equal to 60 years.
  • Patients with history of major affective disorder, including Bipolar disorder type I or type II or major depressive disorder, as assessed by the Structured Clinical Interview for DSM-IV (SCID), currently in remission.
  • Difficulty starting or initiating sleep four or more times/week for at least 3 months by history.
  • Total Pittsburg Sleep Quality Index >5.

排除标准

  • Patient in an acute mood episode as assessed by SCID
  • Patients with sleep disruptive medical problems including: sleep apnea, restless leg syndrome, periodic limb movement, parasomnia, congestive heart failure, chronic pain and chronic obstructive pulmonary disease as assessed by medical history and medical record review.
  • Patients with schizophrenia, primary anxiety disorder and active substance abuse as determined by SCID.
  • Patients on or with history of failure or intolerance to respond to quetiapine.
  • Patient with positive Alcohol Use Disorders Identification Test (AUDIT) with a total score above
  • Patients with dementia brain degenerative diseases, cognitive disorders and Mini Mental Status Examination (MMSE) score of less or equal to
  • Patients who are in an acute depressive, manic, hypomanic or mixed state as reflected by SCID
  • Patients on concurrent sedating medications that would confound interpretation of the results. This is operationalized as follow: Sedating medications must be present and stable dosage for at least 14 days prior to enrollment in the study. If the medication is not prescribed as a primary sleep aid, it will be continued. Our rationale is that patients may need these medications and the initial sedating effect will have plateaued by 14 days. However, medications prescribed to assist insomnia will be discontinued as they are not effective for the subjects who otherwise meet inclusion ad exclusion criteria for the current study. Medications will be tapered as clinically indicated after the patients sing informed consent and prior to baseline assessment.

研究组 & 干预措施

CBT

Active Comparator

干预措施: Quetiapine (Drug)

CBT

Active Comparator

干预措施: Cogntive behavioral therapy (Behavioral)

结局指标

主要结局

PTSQ

时间窗: 12 weeks

次要结局

未报告次要终点

研究者

申办方类型
Fed
责任方
Principal Investigator
主要研究者

Rayan Al Jurdi, MD

PI

Michael E. DeBakey VA Medical Center

研究点 (1)

Loading locations...

相似试验

Group Cognitive Behavioral Therapy (CBT I) Vs.... | 临床试验